Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Aiming to expand its cancer drug portfolio, Boehringer Ingelheim is acquiring the Swiss biotech firm AMAL Therapeutics in a deal worth up to $365 million. The purchase gives Boehringer a cancer vaccine, ATP128, slated to begin human studies later this month in people with late-stage colon cancer. Boehringer says AMAL’s vaccine technology dovetails with its goal of developing a range of treatments that target “cold” tumors—ones that don’t respond to current cancer immunotherapies.
This article has been sent to the following recipient: